Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.

Pharmaceutical

Galectin Therapeutics

Joel Lewis

Marla Mills-Wilson

Seth Zuckerman

Jeff Katstra

Ezra R. Lowe

Susan Thornton

Sharisse Brutto

Jack W. Callicutt

Clinical Operations and Management

Independent Directors

Leadership Team

Teams at Galectin Therapeutics

Clinical Operations and Management

Independent Directors

Leadership Team